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INTRODUCTION
The protein encoded by the MDM2 (Mouse Double 
Minute 2 homolog) gene plays a key role in cell cycle 
control as a regulator of p53 activity (the protein coded 
for by the TP53 gene). It also interacts with several 
other major proteins involved in cell cycle control 
and growth arrest, such as pRb and E2F1 [1, 2]. The 
importance of MDM2 function is illustrated by the fact 
that Mdm2 knock-out leads to early embryonic death in 
mice, which can be reversed by concomitant knockout 
of the TP53 gene [3, 4]. Although lacking in some well 
characterized model organisms, like D.melanogaster 
and C.elegans, homologues of MDM2 have been found 
in many vertebrates as well as invertebrate species [5].
In humans, MDM2 is amplified and / or overexpressed 
in many cancer types [6]. High levels of MDM2 lead to 
increased inhibition and degradation of p53; thus, MDM2 
overexpression has been considered to be one of a set 
of alternative mechanisms of p53 inactivation in several 
tumor forms [7]. 
The polymorphism SNP309T>G (rs2279744), 
located in the MDM2 intronic promoter (P2), has been 
found to be associated with enhanced  Sp1 transcription 
factor binding, thereby leading to increased MDM2 
expression [8]. SNP309G was initially found associated 
with early cancer onset among individuals carrying 
TP53 germline mutations (Li-Fraumeni syndrome) and 
spontaneous soft tissue sarcomas as well as estrogen 
receptor (ER) rich breast cancer [8, 9]. Subsequent to 
the initial discovery of SNP309, potential associations 
between this variant and cancer risk have been studied 
across many cancer types and ethnic groups. Overall, the 
findings indicate that the SNP309G allele is associated 
with an increased risk of several cancer forms in Asian 
populations while the results in Caucasians are at variance 
[10, 11], and a study of >5,000 Western European breast 
cancer patients [12] yielded no associations with cancer 
risk.  Recently, we reported a second SNP (SNP285 
G>C; rs117039649) in the same promoter (P2), only 24 
bps upstream of SNP309 [13]. SNP285C is in complete 
linkage disequilibrium with SNP309G in large previously 
analyzed Caucasian cohorts (>7,000 individuals; p<1.0 
x 10-10 [13]). SNP285C reduces the binding strength 
between the Sp1 transcription factor and the MDM2 
promoter, and is associated with a significantly reduced 
risk of spontaneous breast, endometrial and ovarian cancer 
as well as a reduced risk of ovarian cancer among BRCA1 
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ABSTRACT
The MDM2 promoter SNP285C is located on the SNP309G allele. While SNP309G 
enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C 
antagonizes Sp1 binding and reduces the risk of breast-, ovary- and endometrial 
cancer. Assessing SNP285 and 309 genotypes across 25 different ethnic populations 
(>10.000 individuals), the incidence of SNP285C was 6-8% across European 
populations except for Finns (1.2%) and Saami (0.3%). The incidence decreased 
towards the Middle-East and Eastern Russia, and SNP285C was absent among Han 
Chinese, Mongolians and African Americans. Interhaplotype variation analyses 
estimated SNP285C to have originated about 14,700 years ago (95% CI: 8,300 – 
33,300). Both this estimate and the geographical distribution suggest SNP285C 
to have arisen after the separation between Caucasians and modern day East 
Asians (17,000 - 40,000 years ago). We observed a strong inverse correlation (r = 
-0.805; p < 0.001) between the percentage of SNP309G alleles harboring SNP285C 
and the MAF for SNP309G itself across different populations suggesting selection 
and environmental adaptation with respect to MDM2 expression in recent human 
evolution. In conclusion, we found SNP285C to be a pan-Caucasian variant. Ethnic 
variation regarding distribution of SNP285C needs to be taken into account when 
assessing the impact of MDM2 SNPs on cancer risk.
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mutation carriers [13-15]. Further, censoring individuals 
harboring SNP285C revealed a stronger effect of SNP309 
status on the risk of these cancers [13, 15].  In contrast, 
SNP285C was not associated with an altered risk of 
prostate cancer [15]. The SNP285C variant was detected 
in about 8% among healthy individuals in Norway, the 
Netherlands, and UK, but was absent among Han Chinese, 
and found at a low frequency (<2%) among Finns [13]. 
Given that SNP285C seems to be a significant 
cancer risk reducing factor, any difference related 
to its frequency across populations will add to our 
understanding of differences in cancer risk between 
ethnic groups. Further, this variant may confound cancer 
risk evaluations related to other SNPs in the MDM2 gene 
(such as SNP309) depending on the ethnic population 
investigated. Based on our previous findings [16], we 
hypothesized the SNP285C variant to occur among 
North-Western Europeans only. Here, we determined 
SNP285C distribution across multiple ethnic groups and 
estimated its time of origin. Our results are consistent 
with SNP285C being a pan-Caucasian variant originated 
shortly after divergence between modern day Caucasians 
and East Asians, suggesting SNP285C to be a cancer risk 
modulating factor in all populations of Caucasian origin.
RESULTS
Ethnic distribution of MDM2 SNP285C
The genotypes and allele frequencies for MDM2 
SNP285 are summarized in Table 1A/B and Figure 1. 
The corresponding data for SNP309 is summarized in 
Supplemental Table S1. For all populations analyzed, the 
genotype frequencies are in Hardy-Weinberg equilibrium 
(all p-values >0.3).
In a previous publication, we reported the SNP285C 
variant to be present in about 7.8 % of North-Western 
Caucasians (Norway, the Netherlands and UK) but to 
occur at a low incidence among Finns (1.7%), and to 
be absent in a cohort of Han Chinese [13]. We therefore 
hypothesized that SNP285C could be a young variant, 
present in the North Western part of Europe only. In the 
present study, we found similar SNP285C frequencies 
across Western as well as Eastern  European populations 
(with the exception of the Saami and Finnish populations), 
only dropping off towards the Middle-East  (Greece 5.4%, 
Turkey 4.5%, Lebanon 3.8% and Iran 4.7%) and towards 
the Eastern Russian regions (Altaians in South Siberia 
3.6% and Bashkirs in Ural 3.5%). These data clearly 
indicate SNP285C to be a pan-European variant (Table 
1, Figure 1).
We found no individuals with SNP285C in a sample 
of ethnic Mongolians (n=229). Together with our previous 
data from a Chinese cohort, this confirms SNP285C to 
be absent from East Asian populations. Nor did we find 
any individuals with SNP285C in a cohort of African-
Americans (n=50), strongly indicating this variant to be 
restricted to Caucasian populations. Notably, the frequency 
of SNP285C in our new independent cohort of Finns 
analyzed here (0%; 0 out of 69 individuals), confirmed the 
low frequency found in our previously reported cohort of 
Finns (1.7%; 1.2%, the two cohorts taken together; Table 
1). As for individuals of Saami heritage, SNP285C was 
detected heterozygously in one out of 349 individuals only 
(0.3%; Table 1). 
Figure 1: Distribution of MDM2 promoter SNPs across Eurasia. (A) Distribution of SNP309G. Green dots represent populations 
genotyped. (B) Distribution of SNP285C among SNP309G-alleles. 
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Validation data set for population distribution of 
MDM2 SNP285C
In order to validate our findings with respect to 
the variant frequencies, we mined the 1000 Genomes 
project data bank (www.1000genomes.org), where 
MDM2 SNP309 and SNP285 status are available for 
most individuals. Even though the number of individuals 
here is limited with respect to each ethnic group, these 
additional data support our findings: the SNP285C 
was absent in the Asian populations (Chinese, n=197, 
Japanese, n = 89), while the frequencies (4.1 – 7.1%) in 
the Caucasian populations (Americans, British, Spanish 
and Italians) were in line with our observations. Notably, 
our finding of a low incidence of SNP285C among Finns 
was also validated in the 1000 Genomes data-set (1%). 
Regarding African populations, two individuals (1 out of 
97 Nigerians and 1 out of 88 Kenyans) were registered 
with a SNP285GC genotype in the 1000 Genome project 
databank. However, taking into account that the quality 
scores for the SNP-calling of SNP285 is rather poor for 
these two samples, and the fact that both individuals 
harbor the SNP309TT genotype, the chance exists that the 
registered C-alleles may be artefacts.
Table 1A: Distribution of MDM2 SNP285 genotypes across populations.
Population SNP285 Genotype n (%)
GG GC CC Total
Norway* 2274 (92.3) 183 (7.4) 8 (0.3) 2465
Netherlands* 1089 (92.2) 91 (7.7) 1 (0.1) 1181
UK* 320 (92.8) 25 (7.3) 0 (0.0) 345
Germany 264 (92.0) 23 (8.0) 0 (0.0) 287
Italy 277 (92.3) 23 (7.7) 0 (0.0) 300
Poland 424 (91.2) 40 (8.6) 1 (0.2) 465
Belarus 337 (92.6) 27 (7.4) 0 (0.0) 364
Finland (a)* 179 (98.4) 3 (1.7) 0 (0.0) 182
Finland (b) 69 (100.0) 0 (0.0) 0 (0.0) 69
Saami 348 (99.7) 1 (0.3) 0 (0.0) 349
Greece 282 (94.6) 16 (5.4) 0 (0.0) 298
Spain 272 (94.8) 13 (4.5) 2 (0.7) 287
Estonia 285 (94.1) 18 (5.9) 0 (0.0) 303
Lithuania 283 (94.0) 18 (6.0) 0 (0.0) 301
Ukraine 307 (95.9) 12 (3.8) 1 (0.3) 320
Turkey 401 (95.5) 19 (4.5) 0 (0.0) 420
Lebanon 303 (96.2) 12 (3.8) 0 (0.0) 315
Iran 285 (95.7) 13 (4.4) 1 (0.3) 299
Tver/Ryazan (RUS) 155 (91.7) 14 (8.3) 0 (0.0) 169
North Caucasus (RUS) 279 (93.6) 18 (6.0) 1 (0.3) 298
Bashkirs (RUS) 250 (96.5) 9 (3.5) 0 (0.0) 259
Tadjikistan 281 (92.7) 22 (7.3) 0 (0.0) 303
Altaians (RUS) 243 (96.4) 9 (3.6) 0 (0.0) 252
Mongolia 229 (100.0) 0 (0.0) 0 (0.0) 229
China* 319 (100.0) 0 (0.0) 0 (0.0) 319
Afro-Americans 50 (100.0) 0 (0.0) 0 (0.0) 50
* Previously published data (Knappskog et al 2011).
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Distribution of MDM2 SNP285C among 
SNP309G-alleles
Since the SNP285C variant is present only in 
haplotypes with the SNP309G allele (100% linkage 
disequilibrium with SNP309G), we tested whether any 
of the differences in SNP285C frequencies between 
populations could be “passenger-effects” of the observed 
differences in SNP309 distribution (Supplemental Table 
S1). In order to remove the potential confounding effects 
of different SNP309G frequencies, we compared the 
ratios of SNP285C-alleles divided by the total number 
of SNP309G-alleles between the individual populations. 
Table 1B gives the minor allele frequencies (MAFs) for 
SNP285C among SNP309G alleles. In general, we found 
the same patterns as for the genotypes described above: 
the frequency of the SNP285C / 309G haplotype is quite 
consistent across most Western and Eastern European 
populations (0.066 - 0.120) but low among Saami and 
Finns (0.003 and 0.013, respectively) and dropping off 
towards East Russia and Central Asia, while being absent 
in East Asia and among individuals of African American 
heritage.
Inverse correlation between SNP285 and SNP309 
MAFs
When comparing the frequencies of SNP285C 
and SNP309G across the populations (Table 1 and 
Supplemental Table S1), surprisingly, we found an 
Table 1B: Distribution of MDM2 SNP285 alleles across populations.
Population SNP285 Alleles n (%) MAF 285-MAFamong  309G- alleles
G C Total
Norway* 4731 (96.0) 199 (4.0) 4930 0.040 0.118
Netherlands* 2269 (96.1) 93 (3.9) 2362 0.039 0.117
UK* 665 (96.4) 25 (3.6) 690 0.036 0.105
Germany 551 (96.0) 23 (4.0) 574 0.040 0.066
Italy 577 (96.2) 23 (3.8) 600 0.038 0.107
Poland 888 (95.5) 42 (4.5) 930 0.045 0.073
Belarus 701 (96.3) 27 (3.7) 728 0.037 0.111
Finland (a)* 361 (99.2) 3 (0.8) 364 0.008 0.019
Finland (b) 138 (100.0) 0 (0.0) 138 0.000 0.000
Saami 697 (99.9) 1 (0.1) 698 0.001 0.003
Greece 580 (97.3) 16 (2.7) 596 0.027 0.068
Spain 557 (97.0) 17 (3.0) 574 0.030 0.081
Estonia 588 (97.0) 18 (3.0) 606 0.030 0.090
Lithuania 584 (97.0) 18 (3.0) 602 0.030 0.095
Ukraine 626 (97.8) 14 (2.2) 640 0.022 0.063
Turkey 821 (97.7) 19 (2.3) 840 0.023 0.052
Lebanon 618 (98.1) 12 (1.9) 630 0.019 0.043
Iran 583 (97.5) 15 (2.5) 598 0.025 0.046
Tver/Ryazan (RUS) 324 (95.9) 14 (4.1) 338 0.041 0.120
North Caucasus (RUS) 576 (96.6) 20 (3.4) 596 0.034 0.074
Bashkirs (RUS) 509 (98.3) 9 (1.7) 518 0.017 0.042
Tadjikistan 584 (96.4) 22 (3.6) 606 0.036 0.078
Altaians (RUS) 495 (98.2) 9 (1.8) 504 0.018 0.040
Mongolia 458 (100.0) 0 (0.0) 458 0.000 0.000
China* 638 (100.0) 0 (0.0) 638 0.000 0.000
Afro-Americans 100 (100.0) 0 (0.0) 100 0.000 0.000
* Previously published data (Knappskog et al 2011). 
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inverse correlation (r = -0.439, p = 0.028; Figure 2A). 
This correlation remains after removing the special case 
of African Americans, where SNP285C is absent and the 
frequency of SNP309G is very low (r = -0.607, p = 0.002; 
Figure 2B), as well as after removing all populations 
where SNP285C is absent (African Americans, Chinese 
and Mongolians) from the calculations (r = -0.519, p = 
0.013; correlation plot not shown).
Taking into account the fact that the SNP285C 
variant is found on the SNP309G haplotype only, we 
calculated the correlation between the incidence of the 
SNP285C/309G haplotype among SNP309G alleles 
and the respective SNP309 MAF across the different 
populations. This strengthened the inverse correlation (r = 
-0.604, p = 0.001 and r = -0.805, p < 0.001, including and 
excluding African Americans, respectively; Figure 2C-D).
Ancestry of MDM2 SNP285C
To obtain an estimate of the age of SNP285C, we 
used short tandem repeats (STR) variants surrounding 
the MDM2 locus. Screening 14 STRs in 48 healthy 
Norwegian males, we identified two STRs (D12S1680 
and D12S1693) generating a haplotype (CA)21-(CA)13 
in statistically significant LD with SNP285C. Based on 
this haplotype, the spreading time (age) of SNP285C was 
estimated to be 586 generations (95% CI: 333 – 1333). 
Applying an average generation time of 25 years, we 
estimated SNP285C to be approximately 14,700 years old 
(95% CI: 8,300 – 33,300). Interestingly, recent estimates 
have indicated the separation of present day Caucasians 
and East Asians to have occurred around 23,000 years ago 
(95% CI: 17,000 – 43,000) [17]. Thus, our STR analysis, 
consistent with the geographical distribution of SNP285C, 
suggests this variant to have arisen after the separation of 
Caucasians from modern day East Asians.
Haplotype diversity for MDM2 SNP285C versus 
SNP285G
Finally, we mined the data from the 1000 Genomes 
project, assessing potential differences with respect to 
haplotype diversity between the SNP285C and G alleles. 
While STR genotypes are not available, we extracted 
genotypes for 49 SNPs (including SNP285 and 24 SNPs 
on each side; Supplemental Table S2) in 288 Caucasian 
individuals, enabling us to compare the diversity between 
the alleles carrying SNP285G with those harboring the 
C-variant, across a region of approximately 8.7 kilobases 
(chr12:69197737 – 69206479). The imputed haplotypes 
Figure 2: Inverse correlation between MDM2 SNP285 (rs117039649) and SNP309 (rs2279744). (A-B) Correlation plots 
for MAF SNP285 and MAF SNP309 including all 25 analyzed populations (A) and 24, excluding the special case of African Americans 
where SNP285 is absent and the frequency of SNP309G is very low (B). (C-D) Correlation plots for the frequency of SNP285C among 
SNP309G-alleles in all 25 analyzed populations (C) and excluding African Americans (D).
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Figure 3: (A) Imputed haplotypes including 49 SNPs within / flanking the MDM2 gene, extracted from 288 Caucasian 
individuals; data extracted from the 1000 genome project - www.1000genomes.org. SNP285 (rs117039649) is indicated in 
red. “1” indicates presence of the minor allele for each SNP, while “0” indicates the presence of the major allele. Frequency of the different 
unique haplotypes (n=56) observed among the 576 alleles (288 individuals) are indicated as blue horizontal bars. (B) Haplotype-tree 
based on 8 SNPs surrounding SNP285 (rs117039649). The tree and the frequencies given for each haplotype are based on the same 288 
individuals as in Figure 3A. 
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are depicted in Figure 3A. Among the many haplotypes 
(n=54) carrying the SNP285G-allele, three were 
dominant with respect to frequency while a high number 
of haplotypes were observed in low frequencies (Figure 
3A). In the haplotypes carrying SNP285C (n=16), we 
observed 15 identical ones and a single haplotype carrying 
a SNP-pattern similar to several of the haplotypes with 
SNP285G in the region upstream of this SNP, indicating 
a recombination to have taken place just upstream of 
SNP285.
Regarding SNP285 as the focal point and assessing 
the haplotype branching based on the eight nearest 
neighboring SNPs, we observed a much more complex 
branching pattern for the SNP285G-haplotypes than for 
SNP285C (Figure 3B). These haplotype data indicates 
SNP285C to be much younger than SNP285G, consistent 
with a selective sweep of this variant.
DISCUSSION
While multiple SNPs have been detected throughout 
the MDM2 promoters, effects on transcription and 
pathophysiological effects, such as associations with 
cancer risk, have been described for a few only. While 
SNP309 (rs2279744) seems to have an oncogenic effect, 
and SNP285C (rs117039649) is associated with a reduced 
risk of certain cancers, we found a third SNP in the same 
region (SNP344; rs1196333)  not to be associated with 
altered risk of any of several major tumour forms [18].
So far, apart from our own studies [13, 15], only 
a few studies have assessed SNP285 status. Paulin and 
co-workers found SNP285C in 4.4% of healthy Scottish 
individuals [19], while Piotrowski and colleagues found 
the variant C-allele in 10.2 % of healthy Polish individuals 
[20]. Further, Ryan and colleagues found 6% of Americans 
of Caucasian ancestry to harbor SNP285C  [21], while 
Renaux-Petel and co-workers found this variant among 
5.2% of French individuals diagnosed with germline TP53 
mutations [Li-Fraumeni patients; 22]. Although Ryan et 
al detected SNP285C in 1% of African Americans (3 out 
of 253 genotyped individuals), this observation does not 
contradict the lack of SNP285C in Africans populations, 
as it has been estimated that on average 20% of the gene 
pool in the modern day African-American population is of 
European origin [23]. Taken together, these data are all in 
line with our present findings.
The conclusions from the data presented here are 
also supported by the SNP status from several ethnic 
groups through the genomic data available from the 
1000 Genome project. Further, the distribution pattern 
observed for SNP285C has many parallels known for 
other human genetic variants, including mitochondrial 
DNA and Y-chromosomal haplogroups, being so-called 
West Eurasian [24-26]. 
The reason for the low frequency of SNP285C 
among individuals of Finnish and Saami heritage 
compared to other European populations is unknown. 
However, the Finnish population is known to have 
undergone narrow bottlenecks, and its genetic composition 
differs from other European populations [27]. Notably, the 
low frequency of SNP285C among Finns was detected 
in two independent cohorts and further confirmed in the 
1000 Genome project. Regarding the Saami population, 
it is generally assumed to have originated from a narrow 
subset of Europeans, although their entry route to Northern 
Scandinavia remains an issue of debate [28]. 
Based on the STR analysis, we estimated the age of 
SNP285C to be about 14.700 years. Calculations based 
on nuclear DNA divergence has estimated the separation 
between the European and Asian population to have 
occurred around 23,000 (CI: 17,000 - 40,000)  years 
ago, [17],  while calculations based on mitochondrial 
DNA divergence have estimated this event to take 
place approximately 40,000 years ago [29]. Thus, our 
age estimate, similar to our findings with respect to 
geographical distribution of SNP285C, indicates that 
this variant has arisen early after separation of the two 
population groups.
It should be noted, however, that several theories 
regarding human expansion out of Africa and into the 
rest of the world exist. Probably, neither the expansion of 
humans from Africa nor the split between Caucasians and 
Asians have occurred as single events [30] and our model 
may therefore be too simplistic. Although less likely, 
based on our age estimations and the haplotype diversities, 
SNP285C may have originated early and existed in other 
ethnic groups, including Asians and Africans, only to 
subsequently disappear during evolution. 
Interestingly, we detected a strong inverse 
correlation between the frequency of the SNP285C/309G 
haplotype and SNP309G MAF across the different 
populations analyzed.  While it is not possible to draw 
a definite conclusion with respect to the causes of this 
inverse correlation, it seems clear that this finding may not 
be explained by simple bottleneck effects and subsequent 
rapid expansion of evolutionary neutral variants in a 
population. The fact that SNP285C and SNP309G have 
opposite effects on MDM2 transcription [13] raise the 
question whether such an inverse correlation may be due 
to environmental adaption across different geographic 
areas. Notably, applying a mathematical formulation for 
dating of evolutionary neutral polymorphisms (generations 
= -4Ne [p(lne p) + (1 – p)(lne(1-p)]) [31, 32], with a 
haplotype frequency of 3-4%, SNP285C may be estimated 
to have arisen around 85,000 years ago. The CI for such 
an estimate however will be large [33] precluding any firm 
conclusions to be drawn, but the discrepancy between 
this estimate, the data from geographical distribution and 
STR-based analyses adds support to the hypothesis that 
SNP285C is not evolutionary neutral.
While different studies have shown SNP309 and 
SNP285 to affect the risk for different cancer forms 
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[10, 11], any difference with respect to cancer risk is 
unlikely to have played a major role in evolution, as most 
cancers occur after reproductive age.  MDM2 is a key 
factor in multiple cellular processes; thus, it is likely that 
fine-tuning of its activity in response to environmental 
influences is important. Notably, SNP309 status has 
been associated with missed abortions [34] and with 
male [35] and female [36]  infertility. Taken together, our 
findings indicate both SNP285 and SNP309 status may 
affect biological processes of evolutionary importance. 
SNP285 and SNP309 have been shown to reduce and 
enhance transcription-factor Sp1 binding to the MDM2 
promoter, respectively [13]. Further, they have been 
shown to have opposing effects on cancer risk. Thus, it is 
not unreasonable to postulate they may have antagonistic 
effects on other biological mechanisms as well.
In conclusion, detailed mapping of the prevalence of 
SNP285C in multiple populations indicates this variant to 
be spread through most populations of Caucasian origin. 
The status of this cancer risk reducing SNP needs to be 
taken into account when assessing the impact of other 




In the present project, we screened SNP285 
and SNP309 genotypes in 5,937 healthy individuals, 
representing 21 different populations / cohorts. The 
populations and the number of individuals included in 
each of them are listed in Table 1. In addition, we included 
data from our previous study [13] making the total number 
healthy individuals genotyped 10,429, representing 25 
different populations / cohorts (Table 1), thereby allowing 
us to determine the geographic distributions of both 
variants.
In order to validate our findings, we performed 
data mining and extracted information regarding MDM2 
SNP285 and SNP309 status from genomic information 
from the 1000 Genomes project (www.1000genomes.org). 
Here, we retrieved SNP status from multiple ethnic groups 
mounting up to a total of 1,094 further individuals.
SNP genotyping
The Finnish, Estonian, Lebanese, German and 
Chinese samples were genotyped for SNPs 285 and 309 in 
their respective countries by PCR amplification and Sanger 
sequencing (the three former populations) or restriction 
fragment length analysis (the two latter populations), as 
previously described [13, 37-39]. Norwegian, Dutch and 
British samples were previously genotyped in Norway by 
PCR amplification and Sanger sequencing [13].
The remaining samples were analyzed, for both 
MDM2 SNP285 and 309 status using the LightSNiP 
technology (TIB-MOLBIOL) on a LightCycler 480 
instrument (Roche) in our laboratory in Bergen, Norway. 
These amplifications were performed in a final reaction 
volume of 10 µl, containing 1 µl LightCycler® FastStart 
DNA Master HybProbe mix (Roche Diagnostics), 0.5 µl 
LightSNiP mix (TIB MOLBIOL), 3 mM MgCl2 and 10 - 
50 ng DNA. The thermocycling and melt curve conditions 
were set according to the optimized protocol provided 
by TIB MOLBIOL:  10 minutes initial denaturation / 
activation at 95 °C, followed by 45 cycles of denaturation 
at 95 °C for 10 seconds, annealing for 10 seconds at 60 
°C and elongation at 72 °C for 15 seconds. Subsequently, 
the high resolution melting (HRM) step was performed, 
starting with an initial denaturation at 95 °C for 30 
seconds, followed by melting from 40 °C to 75 °C with 
a ramp rate of 0.19 °C/sec and a final cooling step at 40 
°C for 30 seconds. The HRM curve profiles were then 
analyzed using the Melt Curve Genotyping module in 
the LightCycler® 480 software version 1.5. Both Light 
SNiP assays (for SNP285 and SNP309) had identical 
thermocycling conditions. 
For assay quality control, 3 % of the samples 
analyzed by LightSNiP technology had their genotypes 
validated by Sanger sequencing. The concordance between 
the two methods was 100%, assuring no bias in the data 
sets based on method of genotyping. 
Age estimation of SNP285 by STR genotyping
14 STRs surrounding the MDM2 promoter P2 
were genotyped by PCR amplification and size analyses 
of the amplified products. The STRs and the primers 
used for amplification are listed in Supplemental Table 
S3. Amplification was performed in a 50 µl reaction 
mix containing 0,5 µl Dynazyme EXT polymerase 
(Finnzymes), 1x Dynazyme reaction buffer, 5% DMSO, 
0.2 mM dNTPs, 0.2 µM of each primer and 10-50 ng 
DNA. The thermocycling conditions were a 5 minutes 
initial denaturation / activation step at 95 °C, followed 
by 40 cycles of 45 seconds denaturation at 95 °C, 45 
seconds annealing at 55 °C and 45 seconds elongation at 
72 °C. The amplified products were separated by capillary 
electrophoresis on a ABI3700 sequencer. The STR 
genotyping was performed in a selection of 48 healthy 
Norwegian individuals with known status for MDM2 
SNPs 285, 309 and 344.
Haplotypes were imputed from the SNP and STR 
genotype data, using the Arlequin software v3.5 [40].
The only haplotype (CA)21-(CA)13 at two STRs 
D12S1680 and D12S1693 for which LD with SNP285C 
was statistically significant was identified and used for an 
estimation of the age of SNP285C. We applied the formula 
g = log δ / log (1 - θ) [41], where g equals the time (in 
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generations) back to the initial spreading of mutant 
chromosomes in population, δ equals the measure of LD 
and θ is the recombination fraction between the disease 
locus and the marker. In this case, “mutant” chromosomes 
are SNP285C bearing chromosomes, the “disease locus” 
is the MDM2 gene and the “marker” is the two STRs with 
LD haplotype. To assess the degree of LD, we applied 
the formula δ = (PD – PN) / (1 – PN) [42], where PD is 
the frequency of the associated alleles on the diseased 
chromosome (bearing SNP285C in this case) and PN is the 
frequency of the same allele on the control chromosome 
(not bearing SNP285C). D12S1680 and D12S1693 are 
located in the same linked cluster on genetic Marshfield 
map and so the haplotype (CA)21-(CA)13 was used as a 
single associated allele in the formula. CI for δ was 
calculated as previously described [43]. 
Haplotype diversity
Haplotype diversity for the SNP285G and C-alleles 
were assessed by extracting SNP information from the 
1000 Genomes dataset (www.1000genomes.org). We 
extracted SNP-data from 288 individuals, including all 
Caucasian individuals (possible carriers of SNP285C) 
except for Finns (where the frequency of SNP285C was 
expected to be very low). From these individuals, the 
genotypes of 49 SNPs (Supplemental Table S2), including 
SNP285 and its 24 flanking SNPs on each side (spanning 
a region of 8.7 kb; chr12:69197737 - 69206479) were 
phased using Impute2 [44].
Statistics
Comparisons of genotype distributions between 
population groups were performed by Fisher’s exact 
tests (2x2 comparisons) and Chi-square tests (2xn 
comparisons), using SPSS software, version 18. All 
p-values given are two-sided, and p-values obtained by 
the Fisher’s exact tests are given as cumulative.
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